An observational study in Sickle Cell Disease, Thalassaemia and Congenital Dyserythropoietic Anemia (CDA), sponsored by Hospital Universitari Vall d'Hebron Research Institute. Recruiting at 4 sites in Spain. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Hospital Universitari Vall d'Hebron Research Institute · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Anemia, Sickle Cell with a site in Spain — 8 open to participants now, 12 under way, 5 of them phase 3. Anemia, Sickle Cell · Spain.
Among the 23 studies in Anemia, Sickle Cell with a site in Spain, this one is one of 3 that started in 2020, is one of 7 observational ones, reaches primary completion later than 8 of the 11 other live ones, and was the 23rd registered.
1,136 studies on the registry are indexed under Anemia, Sickle Cell; 240 are open to participants now.
Browse Anemia, Sickle Cell studies →8 of the 23 studies in Anemia, Sickle Cell with a site in Spain are open now. Recruiting first, the newest first:
Sanofi · Sites in Spain, United States, Belgium and 11 more countries
Ages 10–65
Novo Nordisk A/S · Sites in Spain, United States, Australia and 18 more countries
Ages 12+
Novo Nordisk A/S · Sites in Spain, United States, Canada and 14 more countries
Ages 2+
Cyprus Institute of Neurology and Genetics · Sites in Spain, United States, Angola and 13 more countries
Ages 2+
Hospital Universitari Vall d'Hebron Research Institute · Sites in Spain
Ages up to 100
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 177 Anemia, Sickle Cell studies recruiting now, 64 (36%) set no upper age limit and 97 (55%) stop at 75 or younger; 127 take children under 18; 29 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 3 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 350 is above the median of 100 across 297 observational studies indexed under Anemia, Sickle Cell.
Median enrollment 161 across the 16 interventional studies, 1,500 across the 7 observational. Of the 11 that completed or were terminated, 4 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
16 of 23 have an industry lead sponsor. The 10 most frequent:
Hospital Universitari Vall d'Hebron Research Institute is the lead sponsor of 276 studies on the registry; 63 are open to participants now.
Hospital Universitari Vall d'Hebron Research Institute has 6 studies filed under Anemia, Sickle Cell — fewer than ten, so there is no comparison to draw.
4 of the studies in Anemia, Sickle Cell with a site in Spain that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06975865Phase 3SanofiThe Efficacy and Safety of Rilzabrutinib in Participants Aged 10 to 65 Years With Sickle-cell Disease | 2027-07-23 |
| NCT06612268Phase 3Novo Nordisk A/SA Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease | 2027-08-27 |
| NCT06794281Hospital Universitari Vall d'Hebron Research InstituteSynthetic Generation of Hematological Data Over Federated Computing Frameworks: SCD Use Case | 2026-11-30 |
| NCT05799118Cyprus Institute of Neurology and GeneticsStudy of the Role of Genetic Modifiers in Hemoglobinopathies | 2027-09-30 |
Add all 4 to your calendar (.ics) → With an account.
Among the 23 studies in Anemia, Sickle Cell with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
INTEGRA aims at enabling personalized medicine for RADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.
Primary objective
INTEGRA aims at enabling personalized medicine for RADs patients by the establishment of an integrative diagnostic approach based on deep phenotypic and genetic characterization through combining new generation methodologies.
Secondary objectives
The criteria were revised on the registry on Nov 10, 2026. See what changed
Patients, all ages, sustaining a confirmed or suspected diagnosis of an hereditary rare hemolytic anemia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Sickle cell disease (SCD) Thalassaemia syndromes Congenital dyserythropoietic anaemia (CDA) Enzymopathies Unstable / altered oxygen affinity Hereditary stomatocytosis Hereditary pyropoikilocytosis
Hereditary spherocytosis (HS), either severe (baseline Hb \<10 g/dL or transfusion-dependent) or with an inconclusive diagnosis:
Patient with chronic haemolytic anaemia and a compatible red cell smear, but with:
EMA binding test: inconclusive or negative Genetic testing: no definitive diagnosis (VUS or no findings)
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Genetic modifiers for rare anemia disorders will be analyzed through massive sequencing.
Peripheral blood samples will be used for conventional phenotyping characterization including among others: RBCs morphology, fragility osmotic test, hemoglobin fraction and quantification, hemoglobin stability test, EMA binding test, RBC enzymes quantification assay, RBC rheological properties through Lorrca Maxsis Osmoscan/Oxygescan (Lorrca®)
To assess the prognostic value of LoRRca ektacytometry as biomarker providing information of SCD/RADs patients severity
Severity was assesed as the occurence of: * Vaso-occlusive events (VOEs) in the last 24 months * Kidney injury (defined according to KDIGO guidelines) * Retinopathy (defined as proliferative and non proliferative)
Time frame: Through study completion, an average of 2 years
To investigate the correlation between LoRRca ektacytometry parameters and SCD/RADs patients genetic and phenotypic characterization.
Genomic data will be generated using a targeted next-generation sequencing (tNGS) approach. Means, medians, standard deviations (SD), ranges and percentages were calculated using SPSS software (version 20, IBM SPSS Statistics, Chicago, IL, USA). Spearman's rank correlation was used to assess associations between variables. For comparing variables with two categories, either a student's t-test or a Mann-Whitney U test was performed, when appropriate. When the variable had more than two categories, an ANOVA or Kruskal Wallis test was used. A p value \<0.05 was considered statistically significant.
Time frame: Through study completion, an average of 2 year
Started Nov 2020 (actual). Primary completion is estimated for Dec 2028, 97 months after the start.
Of 130 non-industry observational studies under Anemia, Sickle Cell, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 109. This study's planned 97 months is above that.
Counting every sponsor, half of 139 studies reached it within 49 months; a quarter within 24 and three quarters within 109.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 10, 2026: primary completion May 2025 → Dec 2028 and completion May 2028 → May 2031.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitari Vall d'Hebron Research Institute →